Bedrijfsvoering Merck & Co., Inc.

MRK

US58933Y1055

Farmaceutische producten

Beurs gesloten - Nyse Andere beurzen 22:00:02 12-12-2025			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
100,30 ^USD	+1,30%		+0,58%	+0,82%

12/12	Merck ontvangt positief EU CHMP-advies voor uitgebreid gebruik van Winrevair® (Sotatercept) bij volwassenen met pulmonale arteriële hypertensie (PAH, WHO-groep 1 pulmonale hypertensie)	CI
12/12	MERCK & CO., INC. : Morgan Stanley handhaaft het Neutraal advies	ZM

Uitvoerend comité: Merck & Co., Inc.

Bedrijfsleider

Beklede functiesVan

Robert Davis

58 jaar

Chief Executive Officer	01-07-2021
President	01-04-2021

Caroline Litchfield

56 jaar

Director of Finance/CFO

01-04-2021

Kelly E. W. Grez

Corporate Secretary

01-02-2020

Dave Williams

56 jaar

Chief Tech/Sci/R&D Officer

01-08-2020

Sylvia A. Ayler

General Counsel

01-01-2021

Dalton Smart

59 jaar

Comptroller/Controller/Auditor

04-12-2023

Betty Larson

49 jaar

Human Resources Officer

01-04-2024

Jennifer Zachary

47 jaar

General Counsel

01-04-2018

Chirfi Guindo

59 jaar

Sales & Marketing

01-07-2022

Peter Dannenbaum

Investor Relations Contact

01-07-2017

Samenstelling van de raad van bestuur: Merck & Co., Inc.

Directeur

RadenVan

Robert Davis

58 jaar

Governance Committee	08-01-2018
Finance Committee Chair	08-01-2018

Patricia Russo

72 jaar

Finance Committee	09-06-2011
Executive Committee	24-07-2009
Compensation Committee	02-11-2015
Governance Committee Chair	09-06-2011
Governance Committee	02-11-2015
Compensation Committee Chair
Audit Committee	15-06-2023
HR Committee	02-11-2015
Nominating Committee	02-11-2015

Tom Glocer

65 jaar

Compensation Committee	25-05-2016
Governance Committee Chair
Governance Committee	01-01-2021
Nominating Committee	01-01-2021
Audit Committee	25-05-2016

Risa Lavizzo-Mourey

70 jaar

Compensation Committee	26-05-2020
Compensation Committee Chair	20-04-2021
Governance Committee Chair	03-01-2023
Nominating Committee Chair	03-01-2023

Douglas Baker

66 jaar

Compensation Committee	24-03-2015
HR Committee	13-03-2013
Governance Committee
Audit Committee	24-05-2022

Surendralal Karsanbhai

56 jaar

Executive Committee	05-02-2021
Audit Committee	01-01-2025
Governance Committee	01-01-2025

Inge Thulin

71 jaar

Executive Committee	02-06-2011
Compensation Committee	01-03-2018
Governance Committee	01-03-2018

Paul Rothman

66 jaar

Audit Committee	01-09-2015
Compensation Committee	17-05-2024
HR Committee	17-05-2024

Kathy Warden

52 jaar

Audit Committee	16-03-2020
Governance Committee	22-03-2022

Pamela Craig

68 jaar

Governance Committee	01-09-2015
Audit Committee Chair

Christine Seidman

71 jaar

Audit Committee

16-03-2020

Mary Coe

57 jaar

Compensation Committee

Stephen Mayo

63 jaar

Audit Committee

12-07-2022

Recente benoemingen: Merck & Co., Inc.

14/11	Topverhalen rond het middaguur: Merck neemt Cidara Therapeutics over voor $9,2 miljard; Walmart benoemt John Furner tot CEO	MT
27/10	Organon benoemt Joseph Morrissey tot interim-CEO na onderzoek naar mogelijke onregelmatigheden in verkooppraktijken	MT
17/09	Persoverzicht - Financial Times - 17 september	RE
29/07	Belangrijkste Middagverhalen: Amerikaans Handelsdeficit Krimpt in Juni; Novo Nordisk Verrast met Teleurstellende Resultaten en Nieuwe CEO	MT
24/06	Amerikaans CDC-rapport: Geen bewijs voor verband tussen vaccins met thimerosal en autisme	RE
06/03	PERSBERICHT - Wall Street Journal - 6 maart	RE
22/01	Edgewise Therapeutics benoemt Behrad Derakhshan tot COO; aandelen dalen	MT

Meer nieuws

Voormalige zaakvoerders en bestuurders: Merck & Co., Inc.

Insider

Beklede functies

VanTot

James Christopher Scalet

Chief Tech/Sci/R&D Officer

03-11-2009

Samuel O. Thier

Director/Board Member

01-01-1994

03-11-2009

Dennis Erb

Corporate Officer/Principal

04-11-2009

Christopher Garland

Public Communications Contact

04-11-2009

Graeme Bell

Public Communications Contact

04-01-2007

04-11-2009

Stefan Oschmann

Corporate Officer/Principal

01-10-2005

04-11-2009

Steven Kelmar

Public Communications Contact

01-08-2006

04-11-2009

Margaret McGlynn

Corporate Officer/Principal

01-01-2006

01-11-2009

Johnnetta Betsch Cole

Director/Board Member

01-01-1994

01-03-2009

Wendy Yarno

Human Resources Officer	-	-
Sales & Marketing	01-12-1999	01-09-2008

David Anstice

Corporate Officer/Principal	01-01-2003	01-08-2008
President	01-01-2003	01-01-2006

Richard Henriques

Comptroller/Controller/Auditor	01-01-1981	01-01-2008
Corporate Officer/Principal	01-01-1981	01-01-2008

Judy Lewent

Director of Finance/CFO

01-01-1990

01-09-2007

Peter D. Löscher

Corporate Officer/Principal

01-05-2006

31-05-2007

William G. Bowen

Director/Board Member

01-01-1986

24-04-2007

Marcia Avedon

Human Resources Officer

01-01-2002

01-12-2006

Per Wold-Olsen

Corporate Officer/Principal

01-01-1974

01-10-2006

Penny M. Heaton

Chief Tech/Sci/R&D Officer

01-01-1999

01-09-2006

Joan Wainwright

Public Communications Contact

01-06-2000

01-06-2006

Larry Bossidy

Director/Board Member

01-01-1992

01-04-2006

Howard Chin

Corporate Officer/Principal

01-01-2004

31-12-2005

Michael R. Goldberg

Corporate Officer/Principal

01-01-1988

01-01-2005

Heidi Miller

Director/Board Member

01-01-2000

15-12-2004

William Daley

Director/Board Member

01-01-2000

01-01-2004

Wendy Perrow

Corporate Officer/Principal

01-01-1989

Ben Shapiro

Corporate Officer/Principal

01-09-1990

01-07-2003

Paul Howes

Corporate Officer/Principal

01-01-1998

01-06-2003

Patrick Yang

Corporate Officer/Principal

01-01-1992

01-01-2003

Linda Burns

Human Resources Officer

01-01-2002

01-01-2003

Wendy Dixon

Sales & Marketing

01-01-1996

01-11-2001

J. Carroll

Sales & Marketing

01-01-1976

01-01-2001

Beth Seidenberg

Private Equity Investor

01-07-1998

31-03-2000

Thomas A. Reed

Corporate Officer/Principal

01-09-1999

01-03-2000

Albert I. Wertheimer

Corporate Officer/Principal

01-01-1997

01-01-2000

Anne Tatlock

Director/Board Member	03-11-2009	-
Independent Dir/Board Member	04-05-2011	-

Elizabeth Hamilton Seabury Wyatt

Corporate Officer/Principal

01-01-1980

01-01-2000

Kamil Ali-Jackson

General Counsel

01-02-1990

01-07-1998

N. Coles

Corporate Officer/Principal

01-01-1992

01-01-1996

C. Boyd Clarke

Corporate Officer/Principal

01-01-1977

01-01-1996

Michael Tarnow

President

01-01-1973

Stewart John Hen

Corporate Officer/Principal

01-01-1990

Jerome C. Keller

Sales & Marketing

01-01-1986

01-01-1993

Richard Markham

Chief Operating Officer	01-01-1973	01-01-1993
President	01-01-1973	01-01-1993

Douglas J. MacMaster

Corporate Officer/Principal

01-01-1961

01-01-1992

Abraham E. Cohen

Corporate Officer/Principal

01-01-1982

01-01-1992

Julian Adams

Corporate Officer/Principal

01-01-1982

31-12-1987

Kenneth R. Nover

Corporate Officer/Principal

01-01-1974

01-01-1987

Kevin P. Brady

Comptroller/Controller/Auditor

01-01-1980

Teresa Leezer

Corporate Officer/Principal

David Popler

Corporate Officer/Principal

Michael N. Sohn

Corporate Officer/Principal

Daisy Fernandez Seebach

Corporate Officer/Principal

Robert Alonso

Corporate Officer/Principal

Maurisa Sommerfield

Chief Tech/Sci/R&D Officer	-	03-05-2011
Corporate Officer/Principal	03-05-2011	-

Al Cini

Corporate Officer/Principal

Frank Adell

Corporate Officer/Principal

David Osborne

Corporate Officer/Principal

Donald S. Parker

Corporate Officer/Principal

Rick Goulburn

Corporate Officer/Principal

Robert O. Likoff

Corporate Officer/Principal

Samantha Weber

Corporate Officer/Principal

Christopher Anderson

Corporate Officer/Principal

Arthur J. Hiller

Corporate Officer/Principal

Howard F. Solomon

Corporate Officer/Principal

Mark Penn

Corporate Officer/Principal

Steven B. Bernitz

Corporate Officer/Principal

Valentin A. Adia

Corporate Officer/Principal

Viren Mehta

Corporate Officer/Principal

Jack Khattar

Corporate Officer/Principal

Michael Derby

Corporate Officer/Principal

Cecil B. Pickett

Corporate Officer/Principal

Michele Washko

Corporate Officer/Principal

Todd F. Kirschner

Corporate Officer/Principal

Liping Fan

Corporate Officer/Principal

Zev S. Scherl

Corporate Officer/Principal

Tim Biro

Chief Operating Officer	-	-
Corporate Officer/Principal	-	26-07-2011

Ting Oei

Corporate Officer/Principal

Scott Schandler

Corporate Officer/Principal

Thomas Salzmann

Corporate Officer/Principal

David T. Molowa

Corporate Officer/Principal

Edward Rhoads

Sales & Marketing

P. Reed Maurer

Corporate Officer/Principal

Debra A. Bollwage

Corporate Secretary

Derek Hodkey

Chief Tech/Sci/R&D Officer

Jon Scanlon

Corporate Officer/Principal

Anne Clothier

Corporate Officer/Principal

Kris Venkat

Corporate Officer/Principal

Michael Giuliani

Corporate Officer/Principal

William Polvino

Corporate Officer/Principal

Anton Clarke Atwell

Corporate Officer/Principal

Timothy Noyes

Corporate Officer/Principal

Rohini Hira

Corporate Officer/Principal

Letty Z. Zemaitis

Corporate Officer/Principal

Leeftijdsdistributie van bedrijfsleiders

Ratio vrouwen/mannen

Man	22
Vrouw	15

Waarvan leden van het uitvoerend comité

Man	5
Vrouw	5

Waarvan bestuurders

Man	9
Vrouw	4

Herzieningen

Révisions CA 1 an

Révisions CA 4 mois

Révisions CA 1 mois

Révisions BNA 1 an

Révisions BNA 4 mois

ESG MSCI

Environnement

Social

Gouvernance

Polémique

Controverses Ethiques

Nee

Controverses sur les droits de l'Homme

Nee

Controverses Subventions fiscales

Nee

Conforme à la finance Islamique

Merck & Co., Inc. is gespecialiseerd in de ontwikkeling, de vervaardiging en de verkoop van therapeutische producten en vaccins die op recept verkocht worden. De omzet per activiteit is als volgt onderverdeeld: - verkoop van farmaceutische producten (69,4%): bestemd voor de behandeling van hoge bloeddruk, osteoporose, atherosclerose, ademhalingsaandoeningen, bacteriële en schimmelziekten, oogaandoeningen en urologische ziekten, acute migraine, haaruitval bij mannen, enz.; - verkoop van vaccins (20%); - verkoop van producten voor diergezondheid (9,2%); - andere (1,4%). De geografische verdeling van de omzet is als volgt: Verenigde Staten (50,3%), Europa-Midden-Oosten-Afrika (21,8%), Latijns-Amerika (5,4%), China (8,6%), Japan (5,1%), Azië-Pacific (4,8%) en andere (4%).

Werknemers

74.000

Sector

Farmaceutische producten

Agenda

15/12 - Onthechting van dividenddividend

Meer informatie over het bedrijf